Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceHint,exchange,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchangeDataDelayedBy,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,IMMVF,,22631600,,,-23445000,,-23445000,,123000,-29082000,-29082000,29205000,,,,,0,123000,29205000,0,5637000,,-23445000,-23445000,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,en-US,US,EQUITY,False,Delayed Quote,USD,13.7,1629913164,0.0,13.7,13.7,13.7,0,0.0,13.7 - 13.7,13.7,finmb_224178960,Other OTC,Immunovia AB (publ),SEK,11,34,2.0,0.17094018,11.7 - 40.0,-26.3,-0.65749997,11.7,40.0,2,PNK,19.108334,-5.408334,-0.28303534,18.155634,-4.455634,-0.2454133,222134544,15,America/New_York,EDT,-14400000,False,False,0,IMMUNOVIA AB,us_market,PRE,,,,40.0,11.7,19.11,18.16,11,34,22.63M,,17.08M,27.62%,14.99%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,-30.63%,,,778.60%,-50.77M,,,,,,,,5.53,,,,,Value,223 63,Healthcare,67,"Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",Lund,46 4 62 75 60 00,Sweden,http://www.immunovia.com,86400,Medicon Village,Diagnostics & Research,ScheelevÃ¤gen 8
t-1,IMMVF,575702000.0,22631600,,,-46119000,,-46119000,24657000.0,-11330000,-38447000,-38447000,10000,-4889000.0,,,,0,152000,38599000,11482000,-7672000,,-46119000,-46119000,23701000.0,1015290000.0,61775000.0,599403000.0,111234000.0,2441000.0,661178000.0,1132000.0,-425334000.0,8315000.0,113980000.0,468462000.0,33787000.0,8315000.0,48701000.0,474796000.0,4353000.0,4255000.0,0.0,-10259000.0,-1245000.0,4597000.0,-1123000.0,31180000.0,-42131000.0,-712000.0,-35757000.0,2450000.0,922000.0,-25338000.0,8113000.0,-693000.0,441009000.0,en-US,US,EQUITY,False,Delayed Quote,USD,13.7,1629913164,0.0,13.7,13.7,13.7,0,0.0,13.7 - 13.7,13.7,finmb_224178960,Other OTC,Immunovia AB (publ),SEK,11,34,2.0,0.17094018,11.7 - 40.0,-26.3,-0.65749997,11.7,40.0,2,PNK,19.108334,-5.408334,-0.28303534,18.155634,-4.455634,-0.2454133,222134544,15,America/New_York,EDT,-14400000,False,False,0,IMMUNOVIA AB,us_market,PRE,,,,40.0,11.7,19.11,18.16,11,34,22.63M,,17.08M,27.62%,14.99%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,-30.63%,,,778.60%,-50.77M,,,,,,,,5.53,,,,,Value,223 63,Healthcare,67,"Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",Lund,46 4 62 75 60 00,Sweden,http://www.immunovia.com,86400,Medicon Village,Diagnostics & Research,ScheelevÃ¤gen 8
t-2,IMMVF,508057000.0,22631600,,,-38064000,,-38064000,20305000.0,-12625000,-35432000,-35432000,58000,-2869000.0,,,,0,37000,35469000,12662000,-2632000,,-38064000,-38064000,125014000.0,1009450000.0,64018000.0,633071000.0,,29643000.0,697089000.0,1130000.0,-379214000.0,1705000.0,3014000.0,510593000.0,33118000.0,1705000.0,51225000.0,517836000.0,7243000.0,,0.0,-11022000.0,-1197000.0,-1197000.0,-338000.0,31180000.0,-45598000.0,-113000.0,-33266000.0,2444000.0,108000.0,-25338000.0,2584000.0,-2192000.0,484718000.0,en-US,US,EQUITY,False,Delayed Quote,USD,13.7,1629913164,0.0,13.7,13.7,13.7,0,0.0,13.7 - 13.7,13.7,finmb_224178960,Other OTC,Immunovia AB (publ),SEK,11,34,2.0,0.17094018,11.7 - 40.0,-26.3,-0.65749997,11.7,40.0,2,PNK,19.108334,-5.408334,-0.28303534,18.155634,-4.455634,-0.2454133,222134544,15,America/New_York,EDT,-14400000,False,False,0,IMMUNOVIA AB,us_market,PRE,,,,40.0,11.7,19.11,18.16,11,34,22.63M,,17.08M,27.62%,14.99%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,-30.63%,,,778.60%,-50.77M,,,,,,,,5.53,,,,,Value,223 63,Healthcare,67,"Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",Lund,46 4 62 75 60 00,Sweden,http://www.immunovia.com,86400,Medicon Village,Diagnostics & Research,ScheelevÃ¤gen 8
t-3,IMMVF,552469000.0,22631600,,,-34099000,,-34099000,14831000.0,-11595000,-28686000,-28686000,-190000,-5478000.0,,,,0,159000,28845000,11754000,-5413000,,-34099000,-34099000,116286000.0,1009449000.0,65796000.0,668755000.0,,30223000.0,734551000.0,1130000.0,-341150000.0,-674000.0,3135000.0,556191000.0,35266000.0,-674000.0,51595000.0,563535000.0,7344000.0,,0.0,-13701000.0,-1276000.0,371397000.0,902000.0,372673000.0,333276000.0,-78000.0,-24342000.0,2450000.0,1383000.0,-25338000.0,5022000.0,-877000.0,528269000.0,en-US,US,EQUITY,False,Delayed Quote,USD,13.7,1629913164,0.0,13.7,13.7,13.7,0,0.0,13.7 - 13.7,13.7,finmb_224178960,Other OTC,Immunovia AB (publ),SEK,11,34,2.0,0.17094018,11.7 - 40.0,-26.3,-0.65749997,11.7,40.0,2,PNK,19.108334,-5.408334,-0.28303534,18.155634,-4.455634,-0.2454133,222134544,15,America/New_York,EDT,-14400000,False,False,0,IMMUNOVIA AB,us_market,PRE,,,,40.0,11.7,19.11,18.16,11,34,22.63M,,17.08M,27.62%,14.99%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,-30.63%,,,778.60%,-50.77M,,,,,,,,5.53,,,,,Value,223 63,Healthcare,67,"Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",Lund,46 4 62 75 60 00,Sweden,http://www.immunovia.com,86400,Medicon Village,Diagnostics & Research,ScheelevÃ¤gen 8
